| Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy DB Johnson, MV Estrada, R Salgado, V Sanchez, DB Doxie, SR Opalenik, ... Nature communications 7 (1), 10582, 2016 | 507 | 2016 |
| Chemokines modulate immune surveillance in tumorigenesis, metastasis, and response to immunotherapy AE Vilgelm, A Richmond Frontiers in immunology 10, 437682, 2019 | 298 | 2019 |
| Regulation of p53 tumor suppressor by Helicobacter pylori in gastric epithelial cells J Wei, TA Nagy, A Vilgelm, E Zaika, SR Ogden, J Romero–Gallo, ... Gastroenterology 139 (4), 1333-1343. e4, 2010 | 204 | 2010 |
| Akt-mediated phosphorylation and activation of estrogen receptor α is required for endometrial neoplastic transformation in Pten+/− mice A Vilgelm, Z Lian, H Wang, SL Beauparlant, A Klein-Szanto, LH Ellenson, ... Cancer research 66 (7), 3375-3380, 2006 | 124 | 2006 |
| Combinatorial approach to cancer immunotherapy: strength in numbers AE Vilgelm, DB Johnson, A Richmond Journal of Leucocyte Biology 100 (2), 275-290, 2016 | 111 | 2016 |
| Targeting aurora kinases limits tumour growth through DNA damage‐mediated senescence and blockade of NF‐κB impairs this drug‐induced senescence Y Liu, OE Hawkins, Y Su, AE Vilgelm, T Sobolik, YM Thu, S Kantrow, ... EMBO molecular medicine 5 (1), 149-166, 2013 | 102 | 2013 |
| PI3K inhibition reduces mammary tumor growth and facilitates antitumor immunity and anti-PD1 responses J Sai, P Owens, SV Novitskiy, OE Hawkins, AE Vilgelm, J Yang, T Sobolik, ... Clinical Cancer Research 23 (13), 3371-3384, 2017 | 98 | 2017 |
| Mdm2 and aurora kinase a inhibitors synergize to block melanoma growth by driving apoptosis and immune clearance of tumor cells AE Vilgelm, JS Pawlikowski, Y Liu, OE Hawkins, TA Davis, J Smith, ... Cancer research 75 (1), 181-193, 2015 | 87 | 2015 |
| Cell therapy with TILs: training and taming T cells to fight cancer A Kumar, R Watkins, AE Vilgelm Frontiers in immunology 12, 690499, 2021 | 82 | 2021 |
| MDM2 antagonists overcome intrinsic resistance to CDK4/6 inhibition by inducing p21 AE Vilgelm, N Saleh, R Shattuck-Brandt, K Riemenschneider, L Slesur, ... Science translational medicine 11 (505), eaav7171, 2019 | 82 | 2019 |
| Interaction of Helicobacter pylori with gastric epithelial cells is mediated by the p53 protein family J Wei, D O'Brien, A Vilgelm, MB Piazuelo, P Correa, MK Washington, ... Gastroenterology 134 (5), 1412-1423, 2008 | 77 | 2008 |
| Connecting the dots: therapy-induced senescence and a tumor-suppressive immune microenvironment AE Vilgelm, CA Johnson, N Prasad, J Yang, SC Chen, GD Ayers, ... Journal of the National Cancer Institute 108 (6), djv406, 2016 | 76 | 2016 |
| Therapeutic prospects for p73 and p63: rising from the shadow of p53 A Vilgelm, W El-Rifai, A Zaika Drug resistance updates 11 (4-5), 152-163, 2008 | 72 | 2008 |
| RAF265 inhibits the growth of advanced human melanoma tumors Y Su, AE Vilgelm, MC Kelley, OE Hawkins, Y Liu, KL Boyd, S Kantrow, ... Clinical cancer research 18 (8), 2184-2198, 2012 | 69 | 2012 |
| Preparation of (−)-Nutlin-3 using enantioselective organocatalysis at decagram scale TA Davis, AE Vilgelm, A Richmond, JN Johnston The Journal of organic chemistry 78 (21), 10605-10616, 2013 | 65 | 2013 |
| Metabolic modulation by CDK4/6 inhibitor promotes chemokine-mediated recruitment of T cells into mammary tumors RV Uzhachenko, V Bharti, Z Ouyang, A Blevins, S Mont, N Saleh, ... Cell reports 35 (1), 2021 | 59 | 2021 |
| Loss of CXCR4 in myeloid cells enhances antitumor immunity and reduces melanoma growth through NK cell and FASL mechanisms J Yang, A Kumar, AE Vilgelm, SC Chen, GD Ayers, SV Novitskiy, S Joyce, ... Cancer immunology research 6 (10), 1186-1198, 2018 | 56 | 2018 |
| Multimodal multiplexed immunoimaging with nanostars to detect multiple immunomarkers and monitor response to immunotherapies YC Ou, X Wen, CA Johnson, D Shae, OD Ayala, JA Webb, EC Lin, ... ACS nano 14 (1), 651-663, 2019 | 54 | 2019 |
| ΔNp73α regulates MDR1 expression by inhibiting p53 function A Vilgelm, JX Wei, MB Piazuelo, MK Washington, V Prassolov, W El-Rifai, ... Oncogene 27 (15), 2170-2176, 2008 | 50 | 2008 |
| Targeted deletion of CXCR2 in myeloid cells alters the tumor immune environment to improve antitumor immunity J Yang, C Yan, AE Vilgelm, SC Chen, GD Ayers, CA Johnson, ... Cancer immunology research 9 (2), 200-213, 2021 | 46 | 2021 |
ann richmondVanderbilt University OR Emory OR Veterans AffairsVerified email at vanderbilt.edu
